Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

摘要: Ramipril/felodipine extended release (ER) [Triapin and Triapin Mite, Unimax] is a once-daily fixed-dose combination of the ACE inhibitor ramipril ER formulation dihydropyridine calcium channel antagonist felodipine. It indicated in adult patients with essential hypertension whose blood pressure (BP) inadequately controlled or felodipine monotherapy. In this patient population, commercially available combinations (i.e. 2.5 mg/2.5 mg 5 mg/5 mg) are more effective at controlling than individual components used as monotherapy same dosages. Likewise, 10 mg, administered The addition low-dose plus (fixed-dose components) to existing antihypertensive regimen also appears provide adequate BP control renal protection hypertensive non-diabetic chronic disease. these patients, was standard-dose ER, but ramipril, providing diastolic (DBP) control, slowing rate regression glomerular filtration. ramipril/felodipine well tolerated dosages, better given twice dosage combination. Overall, be an option for treatment adults that poorly addition, fixed, potential alternative initial management hypertension.